Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer

Saiji Ohga; Katsumasa Nakamura; Yoshiyuki Shioyama; Katsunori Tatsugami; Tomonari Sasaki; Takeshi Nonoshita; Tadamasa Yoshitake; Kaori Asai; Hideki Hirata; Seiji Naito; Hiroshi Honda

doi:10.1093/jrr/rru065

Acute urinary morbidity after a permanent ¹²⁵I implantation for localized prostate cancer

Saiji Ohga, Katsumasa Nakamura, Yoshiyuki Shioyama, Katsunori Tatsugami, Tomonari Sasaki, Takeshi Nonoshita, Tadamasa Yoshitake, Kaori Asai, Hideki Hirata, Seiji Naito, Hiroshi Honda

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

We evaluated the predictive factors of acute urinary morbidity (AUM) after prostate brachytherapy. From November 2005 to January 2007, 62 patients with localized prostate cancer were treated using brachytherapy. The ¹²⁵Iodine (¹²⁵I) seed-delivering method was a modified peripheral pattern. The prescribed dose was 144 Gy. Urinary morbidity was scored at 3 months after implantation. The clinical and treatment parameters were analysed for correlation with AUM. In particular, in this study, Du90 (the minimal dose received by 90% of the urethra), Dup90 (the minimal dose received by 90% of the proximal half of the urethra on the bladder side) and Dud90 (the minimal dose received by 90% of the distal half of the urethra on the penile side) were analysed. We found that 43 patients (69.4%) experienced acute urinary symptoms at 3 months after implantation. Of them, 40 patients had Grade 1 AUM, one patient had Grade 2 pain, and two patients had Grade 2 urinary frequency. None of the patients had ≥Grade 3. Univariate and multivariate analysis revealed that Du90 and Dup90 were significantly correlated with AUM. In this study, Du90 and Dup90 were the most significant predictors of AUM after prostate brachytherapy.

Original language	English
Pages (from-to)	1178-1183
Number of pages	6
Journal	Journal of radiation research
Volume	55
Issue number	6
DOIs	https://doi.org/10.1093/jrr/rru065
Publication status	Published - Nov 1 2014

All Science Journal Classification (ASJC) codes

Radiation
Radiology Nuclear Medicine and imaging
Health, Toxicology and Mutagenesis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jrr/rru065

Cite this

@article{00c40419ddec436bb90be52daca1fa21,

title = "Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer",

abstract = "We evaluated the predictive factors of acute urinary morbidity (AUM) after prostate brachytherapy. From November 2005 to January 2007, 62 patients with localized prostate cancer were treated using brachytherapy. The 125Iodine (125I) seed-delivering method was a modified peripheral pattern. The prescribed dose was 144 Gy. Urinary morbidity was scored at 3 months after implantation. The clinical and treatment parameters were analysed for correlation with AUM. In particular, in this study, Du90 (the minimal dose received by 90% of the urethra), Dup90 (the minimal dose received by 90% of the proximal half of the urethra on the bladder side) and Dud90 (the minimal dose received by 90% of the distal half of the urethra on the penile side) were analysed. We found that 43 patients (69.4%) experienced acute urinary symptoms at 3 months after implantation. Of them, 40 patients had Grade 1 AUM, one patient had Grade 2 pain, and two patients had Grade 2 urinary frequency. None of the patients had ≥Grade 3. Univariate and multivariate analysis revealed that Du90 and Dup90 were significantly correlated with AUM. In this study, Du90 and Dup90 were the most significant predictors of AUM after prostate brachytherapy.",

author = "Saiji Ohga and Katsumasa Nakamura and Yoshiyuki Shioyama and Katsunori Tatsugami and Tomonari Sasaki and Takeshi Nonoshita and Tadamasa Yoshitake and Kaori Asai and Hideki Hirata and Seiji Naito and Hiroshi Honda",

note = "Publisher Copyright: {\textcopyright} The Author 2014. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.",

year = "2014",

month = nov,

day = "1",

doi = "10.1093/jrr/rru065",

language = "English",

volume = "55",

pages = "1178--1183",

journal = "Journal of radiation research",

issn = "0449-3060",

publisher = "Japan Radiation Research Society",

number = "6",

}

TY - JOUR

T1 - Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer

AU - Ohga, Saiji

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Tatsugami, Katsunori

AU - Sasaki, Tomonari

AU - Nonoshita, Takeshi

AU - Yoshitake, Tadamasa

AU - Asai, Kaori

AU - Hirata, Hideki

AU - Naito, Seiji

AU - Honda, Hiroshi

PY - 2014/11/1

Y1 - 2014/11/1

N2 - We evaluated the predictive factors of acute urinary morbidity (AUM) after prostate brachytherapy. From November 2005 to January 2007, 62 patients with localized prostate cancer were treated using brachytherapy. The 125Iodine (125I) seed-delivering method was a modified peripheral pattern. The prescribed dose was 144 Gy. Urinary morbidity was scored at 3 months after implantation. The clinical and treatment parameters were analysed for correlation with AUM. In particular, in this study, Du90 (the minimal dose received by 90% of the urethra), Dup90 (the minimal dose received by 90% of the proximal half of the urethra on the bladder side) and Dud90 (the minimal dose received by 90% of the distal half of the urethra on the penile side) were analysed. We found that 43 patients (69.4%) experienced acute urinary symptoms at 3 months after implantation. Of them, 40 patients had Grade 1 AUM, one patient had Grade 2 pain, and two patients had Grade 2 urinary frequency. None of the patients had ≥Grade 3. Univariate and multivariate analysis revealed that Du90 and Dup90 were significantly correlated with AUM. In this study, Du90 and Dup90 were the most significant predictors of AUM after prostate brachytherapy.

AB - We evaluated the predictive factors of acute urinary morbidity (AUM) after prostate brachytherapy. From November 2005 to January 2007, 62 patients with localized prostate cancer were treated using brachytherapy. The 125Iodine (125I) seed-delivering method was a modified peripheral pattern. The prescribed dose was 144 Gy. Urinary morbidity was scored at 3 months after implantation. The clinical and treatment parameters were analysed for correlation with AUM. In particular, in this study, Du90 (the minimal dose received by 90% of the urethra), Dup90 (the minimal dose received by 90% of the proximal half of the urethra on the bladder side) and Dud90 (the minimal dose received by 90% of the distal half of the urethra on the penile side) were analysed. We found that 43 patients (69.4%) experienced acute urinary symptoms at 3 months after implantation. Of them, 40 patients had Grade 1 AUM, one patient had Grade 2 pain, and two patients had Grade 2 urinary frequency. None of the patients had ≥Grade 3. Univariate and multivariate analysis revealed that Du90 and Dup90 were significantly correlated with AUM. In this study, Du90 and Dup90 were the most significant predictors of AUM after prostate brachytherapy.

UR - http://www.scopus.com/inward/record.url?scp=84931099281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931099281&partnerID=8YFLogxK

U2 - 10.1093/jrr/rru065

DO - 10.1093/jrr/rru065

M3 - Article

C2 - 25062753

AN - SCOPUS:84931099281

SN - 0449-3060

VL - 55

SP - 1178

EP - 1183

JO - Journal of radiation research

JF - Journal of radiation research

IS - 6

ER -